ロード中...
Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study
BACKGROUND: In our previous study, we investigated the efficacy of ipragliflozin, a sodium-glucose cotransporter (SGLT) 2 inhibitor on diabetic nephropathy in patients with type 2 diabetes and demonstrated that ipragliflozin significantly improved diabetic nephropathy in addition to reducing HbA1c a...
保存先:
| 出版年: | J Clin Med Res |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elmer Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6089574/ https://ncbi.nlm.nih.gov/pubmed/30116437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3491w |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|